Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
TRXC

TransEnterix

$4.14

1.3302 (47.34%)

, ISRG

Intuitive Surgical

$353.55

-8.74 (-2.41%)

13:15
10/17/17
10/17
13:15
10/17/17
13:15
Periodicals
TransEnterix CEO won't compete head on with Intuitive Surgical, Reuters says »

The FDA cleared…

TRXC

TransEnterix

$4.14

1.3302 (47.34%)

ISRG

Intuitive Surgical

$353.55

-8.74 (-2.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

PRTK

Paratek Pharmaceuticals

$23.75

-0.65 (-2.66%)

11:55
10/17/17
10/17
11:55
10/17/17
11:55
Conference/Events
Paratek Pharmaceuticals to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

GNCA

Genocea

$1.60

-0.01 (-0.62%)

11:21
10/17/17
10/17
11:21
10/17/17
11:21
Conference/Events
Genocea management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

AMDA

Amedica

$0.29

-0.01049 (-3.46%)

09:06
10/17/17
10/17
09:06
10/17/17
09:06
Hot Stocks
Amedica receives positive Nasdaq listing decision »

Amedica announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLRB

Cellectar Biosciences

$1.71

-0.08 (-4.47%)

08:41
10/17/17
10/17
08:41
10/17/17
08:41
Hot Stocks
Cellectar Biosciences receives additional Japanese patent for CLR 131, CLR 125 »

Cellectar Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIVE

Viveve

$5.09

-0.3 (-5.57%)

08:32
10/17/17
10/17
08:32
10/17/17
08:32
Hot Stocks
Viveve announces regulatory approval for Viveve System in Mexico »

Viveve Medical announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

TGTX

TG Therapeutics

$9.28

-1.725 (-15.68%)

08:16
10/17/17
10/17
08:16
10/17/17
08:16
Recommendations
TG Therapeutics analyst commentary at Jefferies »

TG Therapeutics 16%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMAG

Amag Pharmaceuticals

$16.60

-0.1 (-0.60%)

, ATRS

Antares Pharma

$2.10

-0.225 (-9.70%)

07:54
10/17/17
10/17
07:54
10/17/17
07:54
Recommendations
Amag Pharmaceuticals, Antares Pharma analyst commentary at Janney Capital »

Antares issues with…

AMAG

Amag Pharmaceuticals

$16.60

-0.1 (-0.60%)

ATRS

Antares Pharma

$2.10

-0.225 (-9.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 02

    Feb

  • 14

    Feb

ARDX

Ardelyx

$6.40

-0.875 (-12.03%)

07:41
10/17/17
10/17
07:41
10/17/17
07:41
Initiation
Ardelyx initiated at Leerink »

Ardelyx reinitiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RXDX

Ignyta

$13.40

-0.25 (-1.83%)

07:01
10/17/17
10/17
07:01
10/17/17
07:01
Hot Stocks
Ignyta receives EMA prime designation for entrectinib »

Ignyta announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.